Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Johnson DB, et al. Among authors: schuchter l. J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6. J Clin Oncol. 2014. PMID: 25287827 Free PMC article. Clinical Trial.
Systemic treatment of metastatic melanoma with chemotherapy.
Green RJ, Schuchter LM. Green RJ, et al. Among authors: schuchter lm. Hematol Oncol Clin North Am. 1998 Aug;12(4):863-75, viii. doi: 10.1016/s0889-8588(05)70028-9. Hematol Oncol Clin North Am. 1998. PMID: 9759584 Free article. Review.
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.
Moore HC, Mick R, Solin LJ, Sickles C, Mangan PA, Luger SM, Fox KR, Schuchter LM, Loh E, Porter DL, Schuster S, Buzby GP, Glatstein E, Silberstein LE, Stadtmauer EA. Moore HC, et al. Among authors: schuchter lm. Ann Oncol. 1999 Aug;10(8):929-36. doi: 10.1023/a:1008393204854. Ann Oncol. 1999. PMID: 10509154 Free article. Clinical Trial.
Metastatic melanoma.
Sun W, Schuchter LM. Sun W, et al. Among authors: schuchter lm. Curr Treat Options Oncol. 2001 Jun;2(3):193-202. doi: 10.1007/s11864-001-0033-5. Curr Treat Options Oncol. 2001. PMID: 12057119 Review.
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. Flaherty KT, et al. Among authors: schuchter lm. Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.
Drug targeting of oncogenic pathways in melanoma.
Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT. Fecher LA, et al. Hematol Oncol Clin North Am. 2009 Jun;23(3):599-618, x. doi: 10.1016/j.hoc.2009.03.004. Hematol Oncol Clin North Am. 2009. PMID: 19464605 Review.
226 results